Despite evidence that SGLT2 polymorphisms may play a role in glycemic control, more evidence on their impact on the outcomes of treatment with SGLT2 inhibitors is needed before genetic information might be used for the further personalization of T2DM treatment. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.